Pacer Advisors’s Charles River Laboratories CRL Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $423K | Sell |
2,454
-1,431
| -37% | -$265K | ﹤0.01% | 1542 |
|
|
2025
Q4 | $775K | Sell |
3,885
-6,676
| -63% | -$1.21M | ﹤0.01% | 1587 |
|
|
2025
Q3 | $1.65M | Sell |
10,561
-812
| -7% | -$129K | ﹤0.01% | 1174 |
|
|
2025
Q2 | $1.73M | Buy |
11,373
+8,804
| +343% | +$1.17M | ﹤0.01% | 1079 |
|
|
2025
Q1 | $387K | Sell |
2,569
-1,517
| -37% | -$254K | ﹤0.01% | 1577 |
|
|
2024
Q4 | $754K | Sell |
4,086
-1,281
| -24% | -$247K | ﹤0.01% | 1474 |
|
|
2024
Q3 | $1.06M | Buy |
5,367
+252
| +5% | +$52.4K | ﹤0.01% | 1321 |
|
|
2024
Q2 | $1.06M | Buy |
5,115
+1,604
| +46% | +$363K | ﹤0.01% | 1259 |
|
|
2024
Q1 | $951K | Buy |
3,511
+94
| +3% | +$22.4K | ﹤0.01% | 1274 |
|
|
2023
Q4 | $808K | Sell |
3,417
-3,669
| -52% | -$722K | ﹤0.01% | 1312 |
|
|
2023
Q3 | $1.39M | Buy |
7,086
+902
| +15% | +$185K | 0.01% | 713 |
|
|
2023
Q2 | $1.3M | Buy |
6,184
+2,417
| +64% | +$481K | 0.01% | 930 |
|
|
2023
Q1 | $760K | Buy |
3,767
+3,586
| +1,981% | +$813K | ﹤0.01% | 1036 |
|
|
2022
Q4 | $39.4K | Sell |
181
-43,458
| -100% | -$9.49M | ﹤0.01% | 2935 |
|
|
2022
Q3 | $8.59M | Buy |
43,639
+40,889
| +1,487% | +$8.83M | 0.06% | 277 |
|
|
2022
Q2 | $588K | Buy |
2,750
+109
| +4% | +$26.6K | ﹤0.01% | 656 |
|
|
2022
Q1 | $750K | Buy |
2,641
+66
| +3% | +$20.4K | 0.01% | 1148 |
|
|
2021
Q4 | $970K | Sell |
2,575
-1,561
| -38% | -$606K | 0.01% | 1222 |
|
|
2021
Q3 | $1.71M | Sell |
4,136
-29
| -0.7% | -$12K | 0.02% | 716 |
|
|
2021
Q2 | $1.54M | Sell |
4,165
-1,137
| -21% | -$380K | 0.02% | 685 |
|
|
2021
Q1 | $1.54M | Sell |
5,302
-112
| -2% | -$31.1K | 0.03% | 600 |
|
|
2020
Q4 | $1.35M | Sell |
5,414
-5,986
| -53% | -$1.43M | 0.03% | 570 |
|
|
2020
Q3 | $2.58M | Buy |
+11,400
| New | +$2.37M | 0.05% | 321 |
|
|
2020
Q1 | – | Sell |
-16,591
| Closed | -$2.53M | – | 765 |
|
|
2019
Q4 | $2.53M | Sell |
16,591
-1,240
| -7% | -$172K | 0.11% | 191 |
|
|
2019
Q3 | $2.36M | Sell |
17,831
-1,361
| -7% | -$182K | 0.05% | 415 |
|
|
2019
Q2 | $2.72M | Buy |
+19,192
| New | +$2.6M | 0.07% | 339 |
|
|
2019
Q1 | – | Sell |
-173
| Closed | -$20K | – | 749 |
|
|
2018
Q4 | $20K | Sell |
173
-17,098
| -99% | -$2.14M | ﹤0.01% | 387 |
|
|
2018
Q3 | $2.32M | Buy |
17,271
+2,112
| +14% | +$261K | 0.09% | 271 |
|
|
2018
Q2 | $1.7M | Buy |
15,159
+2,034
| +15% | +$220K | 0.08% | 349 |
|
|
2018
Q1 | $1.4M | Buy |
13,125
+1,941
| +17% | +$209K | 0.08% | 327 |
|
|
2017
Q4 | $1.22M | Buy |
11,184
+3,948
| +55% | +$430K | 0.09% | 323 |
|
|
2017
Q3 | $782K | Buy |
7,236
+958
| +15% | +$98.4K | 0.07% | 415 |
|
|
2017
Q2 | $635K | Buy |
6,278
+667
| +12% | +$61.4K | 0.06% | 459 |
|
|
2017
Q1 | $505K | Buy |
5,611
+1,015
| +22% | +$86.2K | 0.06% | 482 |
|
|
2016
Q4 | $350K | Buy |
4,596
+317
| +7% | +$24.1K | 0.05% | 590 |
|
|
2016
Q3 | $357K | Buy |
4,279
+360
| +9% | +$30.2K | 0.05% | 512 |
|
|
2016
Q2 | $323K | Buy |
+3,919
| New | +$323K | 0.05% | 535 |
|
Other funds holding CRL
VCM
VPM
Pacer Advisors's CRL Position: Q1 2026 in Review
Pacer Advisors reduced its Charles River Laboratories (CRL) stake by 37% in Q1 2026, selling an estimated $265K and leaving 2,454 shares worth $423K. The position accounts for ﹤0.01% of the portfolio, ranked #1542.
Pacer Advisors first reported a position in CRL in Q2 2016 and has held it in 37 quarters since. The position peaked at $8.59M in Q3 2022. 557 funds tracked by Wall St. Rank hold CRL as of Q1 2026.
- Pacer Advisors held 2,454 shares of Charles River Laboratories worth $423K as of Q1 2026.
- Pacer Advisors sold 1,431 Charles River Laboratories shares in Q1 2026, an estimated $265K.
- Charles River Laboratories made up ﹤0.01% of Pacer Advisors's portfolio in Q1 2026, its #1542 holding.
- Pacer Advisors first reported a position in Charles River Laboratories in Q2 2016 and has held it in 37 quarters since.
- Pacer Advisors's Charles River Laboratories position peaked at $8.59M in Q3 2022.
- 557 funds tracked by Wall St. Rank held Charles River Laboratories as of Q1 2026.
Based on Pacer Advisors's 13F filing for Q1 2026, filed 6 May 2026.